Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk wins European approval for Refixia

Plans to launch the haemophilia B treatment in the fourth quarter

Novo Nordisk

Novo Nordisk has won EU approval for its new haemophilia drug Reflixia and is planning its first European launches in the fourth quarter.

The European Commission marketing authorisation comes one week after US regulators gave the green light to the drug, which is a long-acting Factor IX treatment for haemophilia B.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: "We are excited about the approval of Refixia in the EU, and we consider it an important expansion of the treatment options for patients with haemophilia B.

"The strong clinical profile of Refixia provides haemophilia B patients with better protection against bleeds, even into damaged joints, and an overall improved quality of life."

The half-life of Refixia (nonacog beta pegol or N9-GP) is around five times longer

than standard factor IX products, meaning fewer injections are needed,

Consequently Novo is hoping the new product will help defend its franchise from rival long-acting haemophilia B drug Alprolix (eftrenonacog alfa) from Biogen and Swedish Orphan Biovitrum which was approved in the EU last year.

Article by
Dominic Tyer

7th June 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics